Trends in cocaine and crystal methamphetamine injection over time in a Canadian setting between 2008 and 2018
Bach P, Ti L, Hayashi K, Cui Z, Milloy MJ, Fairbairn N., J Subst Use Addict Treat. 2023
Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis
Eugenia Socias M, Choi JC, Fairbairn N, Johnson C, Wilson D, Debeck K, Brar R, Hayashi K, Int J Drug Policy. 2023
Differentiating the role of alcohol in young men’s use of substances with sex: A qualitative study
Goodyear T, Oliffe JL, Parent N, Mniszak C, Jenkins E, Knight R., Harm Reduct J. 2023
Supervised smoking facility access, harm reduction practices, and substance use changes during the COVID-19 pandemic: a community-engaged cross-sectional study
van Draanen J, Hamilton J, Morgan J, Maxwell S, Taylor T, Richardson L, Nolan S., Harm Reduct J. 2023
Operating an overdose prevention site within a temporary emergency shelter during the COVID-19 pandemic
Galarneau LR, Speed K, Taylor M, Hyshka E., Can J Public Health. 2023
Changements climatiques et comportements liés à l’usage de substances : un cadre des voies de risque
Vergunst F, Berry HL, Mineur K, Chadi N., Perspectives sur la science psychologique, 2023
Changements climatiques et comportements liés à l’usage de substances : un cadre des voies de risque
Vergunst F., Berry H.L., Mineure K., Chadi N., Perspectives sur la science psychologique, 2023
Experiencing homelessness and progression through the HIV cascade of care among people who use drugs
Reddon H, Fairbairn N, Grant C, Milloy MJ., AIDS. 2023
Development of a neural network model to predict the presence of fentanyl in community drug samples
Ti L, Grant CJ, Tobias S, Hore DK, Laing R, Marshall BDL., PLoS One. 2023
Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial
Mocanu V, Bozinoff N, Wood E, Jutras-Aswad D, Le Foll B, Lim R, Cheol Choi J, Yin Mok W, Eugenia Socias M; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse.,
